Claims
- 1. A method for treating strabismus, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.
- 2. The method of claim 1, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
- 3. The method of claim 1, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.
- 4. The method of claim 1, wherein the botulinum toxin is a botulinum toxin type A.
- 5. A method for treating strabismus, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.
- 6. A method for treating blepharospasm, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.
- 7. The method of claim 6, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
- 8. The method of claim 6, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.
- 9. The method of claim 6, wherein the botulinum toxin is a botulinum toxin type A.
- 10. A method for treating blepharospasm, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.
- 11. A method for treating cervical dystonia, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.
- 11. The method of claim 11, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
- 12. The method of claim 11, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.
- 13. The method of claim 11, wherein the botulinum toxin is a botulinum toxin type A.
- 14. A method for treating cervical dystonia, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.
- 15. A method for treating neuromuscular disorders, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.
- 16. The method of claim 15, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
- 17. The method of claim 15, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.
- 18. The method of claim 15, wherein the botulinum toxin is a botulinum toxin type A.
- 19. A method for treating a neuromuscular disorder, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.
- 20. A method for treating a cholinergic influenced secretion, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein.
- 21. The method of claim 20, wherein the botulinum toxin is selected from the group consisting of botulinum toxin types A, B, C, D, E, F and G.
- 22. The method of claim 20, wherein the neurotoxic component of the botulinum toxin has a molecular weight of about 150 kilodaltons.
- 23. The method of claim 20, wherein the botulinum toxin is a botulinum toxin type A.
- 24. The method of claim 20, wherein the cholinergic influenced secretion is a sweat secretion.
- 25. A method for treating a cholinergic influenced secretion, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.
- 26. A method for treating a cholinergic influenced sweat secretion, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin type A substantially free of a botulinum toxin complex protein.
- 27. A method for treating a neuromuscular disorder or a cholinergic influenced secretion, the method comprising the step of administering to a patient a therapeutically effective amount of a neurotoxic component of a botulinum toxin substantially free of a botulinum toxin complex protein, wherein the neurotoxic component has a molecular weight of about 150 kilodaltons.
CROSS REFERENCE
[0001] This application is a continuation in part of application Ser. No. 08/627,118, filed Apr. 3, 1996, which is a continuation of application Ser. No. 08/173,996, filed Dec. 28, 1993, now abandoned, the entire contents of which prior patent applications are incorporated herein by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
08173996 |
Dec 1993 |
US |
Child |
08627118 |
Apr 1996 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08627118 |
Apr 1996 |
US |
Child |
10726904 |
Dec 2003 |
US |